WeChat Mini Program
Old Version Features

Datopotamab Deruxtecan Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: A Cost-Effectiveness Analysis

Chenfeng Tan,Jiaqi Han,Bin Zeng,Zhongzheng Xiang,Yuanyuan Zeng,Jun Wang,Xiaoyuan Wei,Zelei Dai,Ningyue Xu, Wenju Xiong,Lei Liu

Lung Cancer（2024）

Cited 0|Views1
Key words
Antibody-drug conjugate,Datopotamab deruxtecan,TROP-2,Chemotherapy,Cost-effectiveness,NSCLC
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined